Tag Archives: Hunter-Hopkins Center

Ampligen – AIM doses first ‘long hauler’ patient in trial of post-Covid-19 infection

Posted on 01/13/2021 by wames

Clinical Trial Arena: AIM doses first ‘long hauler’ patient in trial of post-Covid-19 infection, 7 January 2021   AIM ImmunoTech has dosed its first Covid-19 ‘long hauler’ patient in the active AMP-511 Expanded Access Program (EAP) with the Ampligen (rintatolimod) … Continue reading →

Posted in News | Tagged , , , , , , , | Comments Off on Ampligen – AIM doses first ‘long hauler’ patient in trial of post-Covid-19 infection